Origin Achieves ISO 13485 Certificate for Best Practice in Medical Devices
ISO 5 cleanroom contract manufacturing
Origin have invested £12 million in a state-of-the-art ISO 5 filling facility. As part of the facility we have developed a kitting service.
As a leading UK pharmaceutical packaging company, Origin are pleased to announce we have been awarded ISO 13485 certification following an in-depth audit.
The internationally agreed ISO standard is the main standard for medical devices and demonstrates to regulators our ongoing commitment to quality and best practice.
ISO 13485 is a stringent standard Origin can apply to control systems and processes to ensure the safety and efficacy of its medical devices.
The certification will support ongoing customer partnerships and open new opportunities where ISO 13485 is a pre-requisite for doing business, assuring customers that the Medical Device / IVD products they intend to purchase will meet their requirements for quality.
It will also allow Origin to sell medical devices in major markets such as the EU and Canada.
The achievement follows years of investment by Origin into state-of-the-art facilities, the introduction of nearly 50 new QMS policies and procedures, the allocation of over 750 work hours to audit-related activity, and two compliance audits by the certification body with involvement from many departments.
Gaining ISO 13485 status will help Origin achieve its business goals of growing its reputation within the competitive healthcare sector – particularly among big pharma, upholding customer satisfaction, promoting better decision making, creating a culture of continual improvement and increasing employee engagement.
Staff across the business have access to standards documentation, helping to identify any issues, improve products and streamline the manufacturing process.
All ISO standards are reviewed every five years to consider whether revision is required to keep it current and relevant for the marketplace. ISO 13485 (2016) is designed to respond to the latest quality management system practices, including changes in technology and regulatory requirements and expectations.
Rich Quelch, Global Head of Marketing commented:
“Being awarded ISO 13485 status is a testament to Origin’s commitment to the highest safety and quality standards in its medical devices and packaging. We’re incredibly proud of this achievement and it marks an important milestone for Origin – it will support us to engage with more pharmaceutical and healthcare companies globally.”
Related News
-
Sponsored Content CPHI Online Trend Report: How can flow chemistry help businesses achieve their sustainability goals?
In our latest CPHI Online Trend Report, we partner with Asymchem to understand the innovative potential of flow chemistry for API manufacturing, especially in regards to meeting sustainability goals.
-
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
Sponsored Content Discover Our Organic Mineral Salts as APIs
Discover the range of organic mineral salts that serve as Active Pharmaceutical Ingredients available from Dr. Paul Lohmann®.
-
Sponsored Content CPHI Podcast Series: Ursatec – celebrating 30 years of pioneering preservative free
In the latest episode of the CPHI Podcast Series, Digital Editor Lucy Chard spoke with Dominik Rocchi of Ursatec.
-
Sponsored Content How healthcare trends inform dosage forms
Capsules encompass one of the most popular solid oral dosage forms for pharmaceutical products, with the global empty capsule market predicted to rise to USD $3.7 billion by 2026. The growth in the capsule market can be partly attributed to the many op... -
Sponsored Content Pharma Trend Outlook: Pharma 4.0 and Industry Resilience
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain.
-
Sponsored Content CPHI Podcast Series: Key Considerations in Selecting the Right CMO Partner
In this month's episode we hear from Jayna Blake, Senior Project Manager for Technical Programs at Baxter BioPharma Solutions, on key considerations for successful CMO selection. -
Sponsored Content Size doesn’t matter: How smaller deals are shaping healthcare M&A
Several mega-deals have made a splash in the pharma and life sciences industries over recent years – from AstraZeneca’s acquisition of Alexion for $39 billion to Gilead Sciences’ $21 billion purchase of Immunomedics. With am...